CD21 Blocking Peptide is synthetically produced from the 915-965 sequence and is suitable for use in western blot applications.
Applications
Immunodepletion/Immunocompetition
Note
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Product Properties
Formulation
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice.
Storage Instruction
Store at-20°C for long term storage. Avoid freeze-thaw cycles.
Synthetic peptide taken within amino acid region 915-965 on human Complement Receptor type 2 isoform X1 protein.
Immunogen Region
915-965
Additional Info
Tissue Specificity
Mature B-lymphocytes, T-lymphocytes, pharyngeal epithelial cells, astrocytes and follicular dendritic cells of the spleen.
Function
Serves as a receptor for various ligands including complement component CD3d, HNRNPU OR IFNA1. When C3d is bound to antigens, attaches to C3d on B-cell surface and thereby facilitates the recognition and uptake of antigens by B-cells. This interaction enhances B-cell activation and subsequent immune responses. Forms a complex with several partners on the surface of B-cells including CD19, FCRL5 and CD81, to form the B-cell coreceptor complex that plays a crucial role in B-cell activation and signaling. Induces also specific intracellular signaling separately from the BCR and CD19 by activating the tyrosine kinase SRC, which then phosphorylates nucleolin/NCL and triggers AKT and GSK3 kinase activities in a SYK/CD19-independent manner. Acts as a ligand for CD23 (FcepsilonRII), a low-affinity receptor for IgE, which is expressed on B-cells and other immune cells, and thus participates in the regulation of IgE production. (Microbial infection) Acts as a receptor for Epstein-Barr virus.
